Umoja Biopharma
Umoja Biopharma develops in vivo CAR T cell therapies that generate cancer-fighting T cells directly in a patient’s body. Its therapies are designed to treat cancers while making treatment more accessible by avoiding the multi-week cell manufacturing required for ex vivo CAR T therapies.
Facts
- HQ
- Seattle, WA 98109
- Sectors
- Biotechnology Research
- Founded
- 2019
- Type
- Corporation Seattle business license
- Employees
- 254
- Registered name
- Umoja Biopharma Inc Seattle business license
- Members see funding amounts. .
Is this your organization? Claim it
BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
BrainChild Bio raises $116M Series A to fund Phase 2 CAR T trial for childhood DIPG
Seattle startup BrainChild Bio raised $116 million in Series A funding to advance a CAR T cell therapy for diffuse intrinsic pontine glioma (DIPG) and to support development of additional pediatric and adult brain tumor CAR T programs. The financing will fund a pivotal ILLUMINATE Phase 2 registration-stage trial and was led by an undisclosed private family fund and foundation, with participation from Seattle Children’s and WRF Capital.
BrainChild Bio raises $116M Series A to fund Phase 2 CAR‑T trial for pediatric diffuse intrinsic pontine glioma
BrainChild Bio raised $116 million in Series A financing to advance CAR-T therapies into the central nervous system, funding a Phase 2 trial of its lead candidate for pediatric diffuse intrinsic pontine glioma while planning future adult indications.
By Umoja Biopharma
See all 5Umoja Biopharma Announces FDA Clearance of IND for UB-VV400, First Known CD22-Directed In Vivo CAR T for Relapsed/Refractory B Cell Malignancies
Umoja Biopharma received FDA clearance for its IND for UB-VV400, the company's lead in vivo CD22-directed CAR T therapy targeting relapsed/refractory B cell malignancies, advancing its clinical pipeline toward first patient dosing.
Umoja Biopharma to Unveil UB-VV500, First In Vivo BCMA × GPRC5D CAR T Therapy for Multiple Myeloma at ASGCT
Umoja Biopharma will present UB-VV500, the industry’s first in vivo CAR T therapy combining BCMA and GPRC5D targeting multiple myeloma, at the ASGCT annual meeting, highlighting its novel dual-antigen approach and planned poster data release.
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors
Umoja Biopharma appointed Dr. Marcela Maus and Dr. Athena Countouriotis to its board of directors, expanding leadership with experienced biotech and cell therapy experts.
People
-
Andy Scharenberg Executive Officer, Director, Co-founder & Chief Executive Officer
-
Michael Jensen Co-Founder
-
Nate Hardy Executive, Chief Financial Officer
Online
Questions about Umoja Biopharma
What is Umoja Biopharma?
Umoja Biopharma is a startup that develops in vivo CAR T cell therapies to generate cancer-fighting T cells directly in a patient’s body, avoiding the multi-week cell manufacturing required for ex vivo CAR T therapies. It is based in Seattle, WA 98109.
What has Umoja Biopharma been in the news for?
WebProNews, GeekWire and American Chemical Society each reported in September 2026 on BrainChild Bio’s plans to fund a Phase 2 CAR T trial for DIPG.
Who are the people behind Umoja Biopharma?
Andy Scharenberg is co-founder and chief executive officer of Umoja Biopharma. Michael Jensen is co-founder, and Nate Hardy is chief financial officer.
Who invested in Umoja Biopharma, and how much has it raised?
Members of Seattle Flow see Umoja Biopharma's funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Umoja Biopharma based?
Umoja Biopharma is based in Seattle, WA 98109.
When was Umoja Biopharma founded?
Umoja Biopharma was founded in 2019.